Post-transplantation diabetes: clinical challenges
The following write up is from the 7th Joint Meeting of ABCD & UKKA 2025 which was held on the 12th February 2025 at the Holiday Inn, Birmingham airport.
DOI:
https://doi.org/10.15277/bjd.2025.483Keywords:
post-transplantation diabetes, kidney transplantation, renal transplantation, immunosuppression, obesityAbstract
Post-transplantation diabetes mellitus (PTDM) is a common complication seen after kidney transplantation and is associated with adverse outcomes. There is a lack of robust evidence-based medicine to guide clinical decision making in the prevention or management of PTDM. Despite the availability of professional society guidelines and expert consensus reports, this paucity of data translates into clinical challenges in day- to-day practice for transplant and diabetes professionals. In this article, four common clinical scenarios associated with PTDM are discussed which offer advice for bridging the gap between evidence- based guidelines and real-world practice.
References
Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabet Med 2021: e14523. https://doi.org/10.1111/dme.14523
Sharif A, Chakkera H, de Vries APJ, et al. International consensus on post- transplantation diabetes mellitus. Nephrol Dial Transplant 2024;39(3):531-https://doi.org/10.1093/ndt/gfad258
Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol 2016;4(4):337-49. https://doi.org/10.1016/S2213- 8587(15)00387-3
Howell M, Tong A, Wong G, Craig JC, Howard K. Important outcomes for kidney transplant recipients: a nominal group and qualitative study. Am J Kidney Dis 2012;60(2): 186-96. https://doi.org/10.1053/j.ajkd.2012.02.339
Singer J, Aouad LJ, Wyburn K, Gracey DM, Ying T, Chadban SJ. The utility of pre- and post-transplant oral glucose tolerance tests: identifying kidney transplant recipients with or at risk of new onset diabetes after transplant. Transplant International 2022;35:10078. https://doi.org/10.3389/ti.22.10078
Oliveras L, Coloma A, Lloberas N, et al. Immunosuppressive drug combinations after kidney transplantation and post- transplant diabetes: a systematic review and meta-analysis. Transplant Rev (Orlando) 2024;38(3):100856. https://doi.org/10.1016/j.trre.2024.100856
Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Guerrero-Romero F. A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacol Res 2016;111:272-82. https://doi.org/10.1016/j.phrs.2016.06.019
Van Laecke S, Nagler EV, Taes Y, Van Biesen W, Peeters P, Vanholder R. The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int 2014;27(9):895-902. https://doi.org/10.1111/tri.12287
Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47(9):1550-6. https://doi.org/10.1007/ s00125-004-1499-z
Kim Y, Jung AD, Dhar VK, et al. Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients. Am J Transplant 2018; 18(2):410-16. https://doi.org/10.1111/ajt.14463
Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial. J Am Soc Nephrol 2021;32(8):2083-98. https://doi.org/10.1681/ASN.2021010127
Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2017; 177(12):1808-17. https://doi.org/10.1001/jamainternmed.20 17.6040
Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 2019;34(2):208-30. https://doi.org/10.1093/ndt/gfy407
Sheu JY, Chang LY, Chen JY, et al. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat Commun 2024;15(1):10043. https://doi.org/10.1038/s41467-024- 54171-8
Polychronopoulou E, Bourdon F, Teta D. SGLT2 inhibitors in diabetic and non- diabetic kidney transplant recipients: current knowledge and expectations. Front Nephrol 2024;4:1332397. https://doi.org/10.3389/fneph.2024.1332397
Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. Prescription patterns of cardiovascular- and kidney- protective therapies among patients with type 2 diabetes and chronic kidney disease. Diabetes Care 2022;45(12): 2900-6. https://doi.org/10.2337/dc22-0614
Chewcharat A, Prasitlumkum N, Thongprayoon C, et al. Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis. Med Sci (Basel) 2020;8(4):47. https://doi.org/10.3390/medsci8040047
Krisanapan P, Suppadungsuk S, Sanpawithayakul K, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clin Kidney J 2024;17(2):sfae018. https://doi.org/10.1093/ckj/sfae018
Published
Issue
Section
License
Copyright (c) 2025 British Journal of Diabetes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Manuscripts published in the June 2024 edition and after in the BJD have been published in open access under a Creative Commons Attribution 4.0 International License and available at https://www.bjd-abcd.com. Prior year articles are available free of charge via our website.
